NR3C2 and heart failure: This participant-level pooled analysis of the three phase 3 trials that have tested the non-steroidal mineralocorticoid receptor antagonist finerenone in patients with heart failure and chronic kidney disease with type 2 diabetes provides an integrated view of the mortality, cardiovascular and renal effects of this treatment.